Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade

Table 3 Biomarker associated risk of toxicity

Clinical or biological marker	Odds ratio	P	95% CI
Interleukin 6	2.84	0.007	1.34–6.03
Sex: female	1.5	0.022	1.06–2.16
Lactic dehydrogenase	1.18	0.645	0.58–2.41
Age	2.82	0.283	0.42–18.81
Interleukin 2	0.74	0.934	0.00–1025.23
Beta2-microglobulin	0.16	0.164	0.01–1.6
Natural Killer cells	0.63	0.593	0.12–3.67
Total lymphocytes	0.28	0.314	0.02–3.36
CD3 lymphocytes	0.41	0.841	0–2500.35
CD4 lymphocytes	2.93	0.722	0.01–1096.90
CD8 lymphocytes	14.04	0.461	0.01–15,879.76
Eosinophils	3.28	0.151	0.65–16.63
S-100 protein	1.05	0.489	0.91–1.21
C reactive protein	2.08	0.308	0.51–8.52
White blood cells	15.02	0.303	0.09–2621.67
Neutrophils	0.59	0.704	0.04–8.95
Vascular endothelial growth factor-A	0.65	0.748	0.04–9.30

The table resumes the odds ratios (OR) for ipilimumab toxicity and significance levels for the markers analyzed in the study (multivariate analysis). Only interleukin 6 and sex had a significant association with the risk of immune-related adverse events (independently of toxicity subgroup). OR for continuous variables refers to the cumulative OR for one unit increase

ISSN: 1479-5876